Anti‐CD19 CAR T‐cell therapy for patients with Richter transformation: A LYSA study from the DESCAR‐T registry

Documenti analoghi

• 672 | REAL‐WORLD DATA OF LISOCABTAGENE MARALEUCEL AS SECOND LINE THERAPY FOR PATIENTS WITH LARGE B‐CELL LYMPHOMA: FIRST RESULTS OF THE FRENCH DESCAR‐T REGISTRY BY LYSA
  di: G. Brisou, et al.
  Pubblicazione: (2025)
• 446 | IMPACT OF RESPONSE TO HOLDING/BRIDGING THERAPY IN SECOND‐LINE DLBCL PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL: A LYSA STUDY FROM THE FRENCH DESCAR‐T REGISTRY
  di: A. Capes, et al.
  Pubblicazione: (2025)
• Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group
  di: Pierre Sesques, et al.
  Pubblicazione: (2026)
• Outcomes and treatment patterns of patients with primary mediastinal B‐cell lymphoma after CAR‐T cell therapy failure: A DESCAR‐T analysis
  di: Jean Galtier, et al.
  Pubblicazione: (2025)
• Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
  di: Jean Galtier, et al.
  Pubblicazione: (2025)